Introduction
This article is an account of research in physiological chemistry, molecular biology, and human genetics that developed the concept that glucokinase (GK)' ofthe insulin-secreting pancreatic /3 cells plays the crucial role of glucose sensor in an endocrine feedback cycle that maintains glucose homeostasis, and traced one cause of non-insulin-dependent diabetes mellitus (NIDDM) to mutations of the GK gene. This body of knowledge promises to be significant for the understanding ofglucose homeostasis in general and ofthe etiology of diabetes mellitus, and also for devising new approaches to the management ofthe disease.
Unique physiological and biochemical design features of glucose metabolism ofpancreatic A3 cells Physiological considerations. The narrow range of physiological blood glucose concentrations (4-8 mM) is governed by the glucose set points and the secretory capacities of the pancreatic a and f3 cells ( 1) . This design feature is illustrated by the concentration dependency curves and the opposite effects of glucose on a and ,3 cells showing a physiological crossover point in the fed state at 5 mM glucose ( Fig. 1 A) . The glucose set point and secretory capacity of the /3 cell play the paramount role in glucose homeostasis, and their physiological or pathological alterations thus influence the average blood glucose levels in a preeminent manner. It cannot be overemphasized that glucose is the only nutrient molecule that stimulates /3 cells directly at physiological levels, and that blood glucose levels of at least 2.5-3.0 mM need to be maintained to allow the recognition by the a cell of other nutrient molecules (i.e., amino acids and ketone bodies) and of hormones or neurotransmitters that stimulate , cell function (e.g., enteroglucagon or acetylcholine) (2). 1 . Abbreviations used in this paper: GK, glucokinase; MODY, maturity-onset diabetes ofthe young; NIDDM, non-insulin-dependent diabetes mellitus.
Unique design features of, cell glucose metabolism. Glucose stimulation of insulin secretion is the result of enhanced glucose metabolism of ,B cells ( 1, (3) (4) (5) (6) . Glucose enters the 3 cells via the high-capacity, high Km hexose transporter, GLUT-2 (6, 7). The capacity of glucose transport in intact islets is at least 100-fold in excess of actual glycolysis and is sufficient to assure equalization of extra-and intracellular glucose within seconds of any blood glucose level changes, pointing to an intracellular glucose sensing device. Glucose transport reductions of > 90% need to take place to exert a marked impact on physiological islet glucose metabolism (7) .
Phosphorylation of glucose is dually controlled by at least one hexokinase (probably hexokinase I) and by GK (3) (4) (5) (6) 8) . Islet tissue hexokinase has relatively broad substrate specificity, has a low Km for glucose of0.05-0.15 mM, and is inhibited "in situ" by > 95% by various phosphorylated intermediates (e.g., glucose-6-phosphate, glucose-l1,6-diphosphate, and 6-phosphogluconate [G-6-P, G-1,6-P2, and 6-GP]), such that flux through hexokinase is relatively slow even when fully saturated at 2 1.0 mM glucose (compare Fig. 1 , B and C). However, flux through hexokinase(s) can be regulated indirectly (8), particularly when glucose levels are low and flux through the high Km system (see below) is relatively slow (4) . Future research should elucidate the precise nature and possible role ofhexokinases other than GK. GK of the ,B cell has by far the lowest capacity of all glycolytic enzymes (3, 4) . It has an apparent Km of -10 mM for glucose and shows cooperative kinetics (the Hill coefficient [nH] = 1.5-1.7) with its substrate glucose (Fig.  2) . The inflection point of the sigmoidal glucose dependency curve of GK is at -5 mM, close to the threshold of/ cells for glucose stimulation. GK prefers the a anomer of glucose. GK lacks significant feedback inhibition by metabolites in contrast to other hexokinases. The fructose-6-phosphate (F-6-P)-dependent GK inhibitor protein found in liver, although present in islets, appears to be of little importance under normal conditions (9 (Fig. 2) . The possibility exists that factors in the ,( cell, yet to be discovered, could modify GK such that the Km or nH for glucose are modified, resulting in a shift of the glucose dependency curve of metabolism and insulin release. Glucose-6-phosphatase, glucose-6-P dehydrogenase, and the glycogen apparatus are other enzyme systems that impinge on G-6-P levels ( 11, 12) . Quantitating precisely the actual rates of all processes governing the level ofG-6-P is a difficult task and has not been accomplished. Subtleties aside, it appears that GK is the principal determinant of altered flux through the G-6-P pool when glucose levels change in the physiological range of 4-8 mM. that GK is the main determinant of glucose usage by (3 cells ( 1, 4, 5). Moreover, GK activity of islet tissue extracts and glucose usage rates of intact islets changed concordantly over a fivefold range in cultured pancreatic islets maintained at 3-30 mM glucose ( 13). Another outstanding feature of pancreatic fl cell metabolism is the high activity of mitochondrial a-glycero-Pdehydrogenase, an enzyme that shuttles hydrogen unidirectionally from the cytosol into mitochondria ( 14) . Glucose stimulates oxygen consumption of islets effectively (15) . Yet (22) (Fig. 3) . It was soon discovered that regulation of GK in hepatocytes and 13 cells was fundaVoltage sensitive mentally different, with glucose governing the level of 1 cell GK and insulin regulating that of hepatocyte GK (23) . Attempts to assess the relative importance ofthe two components in this feedback loop of glucose homeostasis are problematic because ofthe cyclic nature of the process. However, the 1 cell GK link appears to be the component with the highest control strength because there appears to be little or no redundancy, contrasting with the hepatic GK link. After a meal liver GK participates in the removal of elevated blood glucose and its deposition as liver glycogen. However, as much as threefourths of the glycogen may be synthesized by an indirect gluconeogenic pathway from lactate and pyruvate generated in liver, the splanchnic organs, and muscle, in large part independent of GK (24) . A partial reduction of liver GK might therefore be compensated by other processes, as opposed to the case ofa 1 cell GK deficiency. Furthermore, glucose uptake by muscle that is stimulated by insulin participates in glucose disposal.
Cellular heterogeneity ofhepatic and islet GK distribution and intracellular compartmentation ofGKin 13 cells. Pancreatic 13 cells are heterogeneous, as manifest in remarkably different GK contents of individual 1 cells (25) . Some 13 cells are nearly devoid ofimmunoreactive enzyme (Fig. 4) . This cellular heterogeneity of 1 cell GK may be paralleled by cellular heterogeneity of insulin contents and of secretory glucose responsiveness, although a correlation between GK content and insulin-secreting ability has not been established (26) . The significance of cellular heterogeneity of GK distribution for the glucose set point and the nature ofthe glucose dependency curve ofinsulin secretion remain elusive because individual 1 cells do show a graded response to glucose as well, rather than responding in an all or none fashion.
It has been proposed that GK might be compartmentalized within the 1 cell by association with the GLUT-2 transporter at the cell membrane, thus constituting a higher level organization, which might establish a unique metabolic signaling pathway in the 13 cells (27) . This possibility remains to be fully investigated.
Glucokinase gene structure and regulation Tissue-specific GK isoforms. The biochemical and physiological studies that served to define the function of GK in the pancreatic 13 cell and the liver provided a framework for molecular genetic studies. The cDNA sequence ofrat hepatic GK was the first to be determined (28, 29) , and soon thereafter the sequence ofrat 13 cell GK was elucidated (30, 31 Alternate promoters in the GKgene and differential regulation ofhepatic and/3 cell GKgene. An explanation for the origin of the different GK isozymes was found when the structure of the GK gene was determined. Alternate first exon sequences of a single GK gene were found to be used in a tissue-specific manner to produce the different hepatic and pancreatic /3 cell isoforms (31 ) . The different first exons each encode a translation initiation codon and 14 additional amino acids that are alternately spliced to 9 common downstream exons (see Fig.  5 ). The upstream GK promoter is active in the pancreatic A cell while the downstream promoter is active in hepatocytes. The two promoters are widely separated in the GK gene. In the rat they lie at least 15 kb apart. Judging from the lack of sequence similarity and from different patterns of transcription initiation, the two different promoters appear to be functionally distinct.
Identification ofalternate promoters in the GK gene was an observation that supported the GK regulation studies, which established the differential regulation of GK in the liver and : cell (see above and reference 23) and strengthened the model of a regulational feedback loop, involving GK in the liver and the :3 cell (Fig. 3) .
GK gene transcription in liver is affected by several glucoseregulating hormones and other agents, in contrast to the more constitutive expression of the upstream promoter in /3 cells. This allows hepatic GK to be adaptively regulated in response to changes in nutritional and hormonal status, while islet GK remains a more stable determinant ofthe rate ofglucose metabolism and insulin secretion from the /3 cell. Among hormones affecting expression of hepatic GK the effect of insulin is the most pronounced (33, 34). Both biotin and triiodothyronine also stimulate transcription of the GK gene in liver, while glucagon, acting via cAMP, has an opposing effect, both inhibiting GK gene transcription and decreasing the half-life of GK mRNA (35). The regulatory elements mediating transcription of the hepatic GK gene have not been identified.
The activity of GK in the pancreatic /3 cell is induced by glucose and appears to be regulated at a posttranscriptional level ( 13) . We speculate that glucose itself controls the rate of GK degradation and thus the enzyme activity.
A detailed fusion gene analysis of the elements responsible for transcriptional activity in insulinoma cells showed that multiple regions in the proximal portion (-280 (36) . Within this 294-bp fragment of the GK gene are three copies of an element (CAT(T/C)A(C/G) that binds a factor that also binds to both the rat and human insulin genes. The presence of the same element in both the insulin and GK promoters that binds a 13 cell-specific nuclear factor suggests that certain aspects ofgene expression in the pancreatic 1 cell may be, at least in part, coordinately regulated. Human GKgene andpolymorphisms. Structurally, rat and human GK are 97% identical although there are two different hepatic isoforms that differ at the amino terminus in a way similar to the differences between the rat hepatic and islet isoforms (37) . Moreover, the human gene is organized in a manner similar to that ofthe rat with dual promoters that are separated by at least 20 kb (38) . The remainder of the exons, including an alternate cassette second exon, are scattered over 16 kb. The human GK gene exists as a single copy in the genome and is located on chromosome 7p (38) . Highly polymorphic microsatellites have been identified at three positions in the gene, facilitating an analysis ofdiabetic human pedigrees using PCR-based assays, for GK gene mutations.
Genetic GKDefects as cause offamilial early-onset NIDDM Definition of the MODY syndrome and linkage studies with candidate genes. Maturity-onset diabetes of the young (MODY) is a form ofNIDDM characterized by an early age of onset and by autosomal dominant transmission with high penetrance, and appears to be a heterogeneous disorder (39) . The autosomal dominant transmission ofdiabetes in MODY families made these pedigrees attractive for analysis of GK gene mutations.
Molecular genetic, metabolic, and clinical studies were carried out in 32 families with MODY, collected in France. Candidate genes for a pancreatic 1 cell defect (e.g., insulin, GLUT-2, and GK) were investigated, in addition to the ADA region on chromosome 20 (40) . Negative results were found for insulin, GLUT-2, and ADA. In contrast, tight linkage was demonstrated between MODY and DNA polymorphisms near the GK gene. The availability ofthree microsatellites increased the genetic information on the families and together allowed for a maximum lod score between diabetes and GK of more than +25 over all MODY families at a recombination fraction of 0.00. This indicates that the odds in favor of linkage are > 1025:1. Some MODY families showed exclusion of linkage with GK, implying the presence of at least one additional diabetes susceptibility gene, however, the proportion offamilies in which MODY is linked to the GK locus is estimated to be 60%.
Mutations ofthe GKgene in MODYfamilies. The 12 coding exons of the GK gene of the affected individuals were scanned by single-strand conformation polymorphism analysis. Direct sequencing of the amplified exons identified 16 different mutations present only in affected individuals of 18 of the 32 early-onset NIDDM families as compiled in Table I (41). Two of the gene mutations were identical in different kindreds. 50% of the nucleotide substitutions occur in a CpG dinucleotide known to be a hot spot for mutations, findings that argue against a founder effect. In all cases the mutations (nonsense, missense mutations, or deletion) altered the sequence ofGK or resulted in the synthesis ofa truncated protein either by premature termination or by changing the sequence at an exon-intron junction that affected splicing.
Mutations were detected in all the affected young individuals in the MODY pedigrees, however, none of the unaffected individuals showed evidence of mutation. In addition to the French families, linkage to the GK locus has been found in a British MODY family (42) . Glucokinase mutations were also identified in 5% of subjects with gestational diabetes mellitus (43) . 10 of the > 20 known mutant human glucokinases have been expressed in Escherichia coli and have been studied kinetically ( 10, 43, and Matschinsky, F. M., Y. Liang, P. Kesavan, L. Wang, K. Niswender, and M. A. Magnuson, unpublished results). These mutations dramatically decrease the activity and/or the affinity for glucose of this enzyme, vital to hepatocyte and 13 cell glucose metabolism (Table I) .
Pathophysiological consequences of mutations in the GK gene. An insulin secretion defect consistent with the 13 cell GK defect has been identified in MODY patients carrying mutant GK alleles (44) . In the typically heterogeneous MODY patients ,B cell GK is probably reduced by 50%. Therefore, glycolysis and glucose oxidation in 1 cells are likely to be decreased in parallel, resulting in a release profile equivalent to a profile of normal individuals with blood sugar levels one-half to twothirds that of patients. This may explain the autosomal dominant inheritance of MODY. A presumed reduction of GK activity may result from a gene dosage effect.
These MODY data contrast with those in the commonest form of NIDDM with late age of onset, where the first-phase insulin secretory response is characteristically lost when fasting plasma glucose concentration rises to 6.4-6.7 mmol/liter (45 ) . The insulin secretory profile also seems to be different from profiles of MODY patients linked to DNA markers in chromosome 20 (46) , in whom first-phase insulin secretion seems to be drastically reduced.
Perspective
The 13 cell GK glucose sensor concept and the recognition that GK is a significant diabetes mellitus gene greatly expand our understanding of glucose homeostasis both normally and in the pathogenesis of the disease. The significance can be appreciated best by considering the topic at increasing levels oforganizational complexity.
At the molecular level it can be anticipated that clarification of the mechanism of catalysis of glucose phosphorylation will be more effectively sought because of the availability of ample recombinant enzyme protein with specific, functionally significant mutations, and that the unique positive cooperative effect of glucose resulting in a nH of 1.5-1.7 will be intensively studied. The possibilities of allosteric and covalent modifications ofthe enzyme need to be studied carefully. Recombinant human liver and 13 cell GK isoforms can now be produced in milligram quantities, which will allow the crystallographic analysis of the enzyme and its mutant forms.
At the cellular level the nature of metabolic control by GK as pacemaker enzyme of glucose metabolism in pancreatic 13 cells governing ATP generation by the mitochondria needs to be more fully explored. Germ line-altered mouse models ofthe dominantly inherited familial MODY type ofNIDDM need to be generated to study the influence of GK mutants on 1 cell function. This will also allow an extensive evaluation of the relative importance of GK in hepatic and 13 cell metabolism and glucose homeostasis. Moreover, the glucokinase glucose sensor paradigm, which has been useful for the understanding of pancreatic 13 cell function, may also be applicable to other glucose-sensing cell types that appear to exist in the intestine and in the central nervous system (Jetton, T. L., Y. Liang, E. C. Zimmerman, C. C. Pettephen, F. G. Cox, U. Horrath, F. M. Matschinsky, and M. A. Magnuson, manuscript submitted for publication). The concept of intracellular compartmentation of GK offers another fruitful experimental field. At the tissue and organ level the nature ofdifferential regulation of GK gene expression will continue to be an important topic of research aimed at understanding the mechanisms of insulin induction of hepatic GK and of glucose induction of the 1 cell isoform ofthe enzyme. The question ofcellular heterogeneity of GK expression observed both in the acinar unit of the liver and in the islet of Langerhans requires attention to explore the biochemical basis and the functional significance of these striking cellular heterogeneities. Glucose has a priming action on hepatic glycogenesis and lipogenesis from nonglucose precursors. Thus, it remains to be explored whether GK and thus glucose catabolism play a role in this glucose effect and whether genetic GK deficiencies, e.g., in MODY patients, have a functional hepatic manifestation.
At the whole body level it will be possible to exploit the various GK mutants in humans to better understand glucose homeostasis, for example, the nature ofthe ,B cell set point, the modification of the ,B cell set point by neuro-endocrine factors, and the role of the liver in the regulation of blood glucose. The defined GK lesion in MODY patients will make it possible to reassess the contribution of glucose toxicity and insulin deficiency in the genesis of long-term diabetic complications. The role of glucose toxicity in impaired # cell function is also ammenable to reexamination.
At the highest level of organization, the family and population level, the evolution of the GK defect will need to be explored. And, finally, it needs to be investigated whether GK is the target of toxic environmental factors and whether its activity can be beneficially modified by pharmacological and therapeutic intervention.
